<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469896</url>
  </required_header>
  <id_info>
    <org_study_id>2015TCZALS-001</org_study_id>
    <nct_id>NCT02469896</nct_id>
  </id_info>
  <brief_title>A Trial of Tocilizumab in ALS Subjects</brief_title>
  <acronym>TCZALS-001</acronym>
  <official_title>A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barrow Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barrow Neurological Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barrow Neurological Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to find out if tocilizumab, also known as Actemra™, can
      help with Amyotrophic Lateral Sclerosis (ALS). The investigators also want to find out if
      tocilizumab is safe to take without causing too many side effects.

      Currently ALS has no cure and 2 modestly effective treatment to slow the progression of the
      disease. Although not the initial cause of ALS, the immune system plays a role in the death
      of motor neurons. The immune cells that participate in this process are stimulated by a
      substance called interleukin-6 (IL-6) whose effect is blocked by tocilizumab and thus, may
      slow the death of motor neurons and slow the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled 16-week study evaluating
      the safety and tolerability of tocilizumab in subjects with ALS.

      The primary objective of the study is to determine the safety and tolerability of intravenous
      administration of 8 mg/kg of tocilizumab every 4 weeks vs. matched intravenous placebo
      administered every 4 weeks over an 8 week period.

      The secondary objectives of the study are to describe the expression of pro-inflammatory
      genes in Peripheral Blood Mononuclear Cells (PBMCs) of sporadic ALS patients, to assess the
      ability of tocilizumab to reduce the expression of pro-inflammatory genes in PBMCs and
      pro-inflammatory cytokines in the cerebrospinal fluid (CSF) of patients with sporadic ALS and
      to assess the CSF penetration of tocilizumab. Mean peripheral benzodiazepine receptor 28
      (PBR28) uptake will be measured in the motor cortices as regions of interest (ROIs), and will
      be compared between pre- and post-dose, for Massachusetts General Hospital (MGH) subjects.

      Approximately 5 Northeast ALS Consortium (NEALS) Centers in the US will participate in the
      study. Twenty-four subjects will be randomized in the study.

      This study will be conducted in subjects who meet the El Escorial criteria of possible,
      laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS. At
      screening, eligible subjects must be at least 18 years old, must have a slow vital capacity
      (SVC) ≥ 40% of predicted capacity for age, height and gender (and in the opinion of the
      investigator is able to comply with and complete the trial), and must provide written
      informed consent prior to screening. Subjects on a stable dose of riluzole and those not
      taking riluzole, and women of child-bearing age at screening are eligible for inclusion as
      long as they meet specific protocol requirements. Detailed criteria are described in the body
      of the protocol.

      Subjects participating in the magnetic resonance imaging - positron emission tomography
      (MRI-PET) portion of the study (MGH only) must meet the following additional criteria.High or
      mixed affinity to bind translocator protein (TSPO) (Ala/Ala or Ala/Thr,) Upper Motor Neuron
      Burden (UMNB) Scale Score ≥25 (out of 45) at the Screening Visit.

      and have the ability to safely undergo MRI-PET scans based on the opinion of the site
      investigator.

      Subjects will be randomly assigned in a 2:1 ratio to intravenous tocilizumab 8 mg/kg or
      matching placebo every 4 weeks over an 8 week period.

      This research study protocol allows the subject to receive up to 3 infusions of Tocilizumab.
      Even if the treatment is shown to be of benefit, additional infusions of Tocilizumab beyond
      that allowed in the protocol cannot be given to the subject while she/he is participating in
      this study.

      Subjects will remain on randomized, placebo-controlled, double-blind treatment until the Week
      8 visit. Each randomized subject will also have a Week 12 Follow-up visit and Week 16
      End-of-Study visit to assess for adverse events (AEs), changes in concomitant medications, to
      administer the ALS Functional Rating Scale (ALSFRS-R) and selected study procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">July 11, 2018</completion_date>
  <primary_completion_date type="Actual">July 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Tolerant to Study Drug</measure>
    <time_frame>16 weeks</time_frame>
    <description>Tolerability will be assessed by on the proportion of participants remaining on study drug through all 3 doses and remaining on study and free from possibly drug-related and dose-limiting SAEs to the end of follow-up. Safety will be assessed by the occurrence of severe adverse events (SAEs), overall rates of adverse events (AEs), clinically significant abnormal laboratory tests, and changes in vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of All-cause Mortality</measure>
    <time_frame>16 weeks</time_frame>
    <description>Safety will be assessed by the occurrence of all-cause mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Decline in Slow Vital Capacity (SVC)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Efficacy will be assessed by the change in the rate of change of SVC as measured by change in percent predicted per month. The SVC is a measure of lung capacity that is reported as the percent of the predicted value expected based on gender and height. In ALS patients, this measure declines over time as a result of progressive respiratory muscle weakness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Decline ALS Functional Rating Scale Revised (ALSFRS-R)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Efficacy will be assessed by the mean change in ALSFRS-R total score.The ALSFRS-R scale measures the functional capabilities of an ALS patient in multiple domains such as swallowing, speech, fine motor, and breathing functions. It ranges from a maximum score of 48 for normal functioning to 0 for death or dependance on mechanical ventilation and declines by approximately 1 point per month on average for an ALS patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Decline Handheld Dynamometry (HHD)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Efficacy will be assessed by the change in the rate of change of HHD upper and lower extremity mega-scores. HHD utilizes an electronic pressure sensor to measure strength of individual muscles in kilograms. To calculate megascores, the mean and standard deviation of each muscle or muscle group, without regard to laterality, will be calculated from the baseline assessment of all participants. Strength estimates of each bilateral muscle or muscle group will be converted to Z scores by subtracting the relevant mean and dividing by the relevant standard deviation. Z scores for all upper extremity measurements (shoulder flexion, elbow flexion, elbow extension, wrist extension, and first dorsal interosseous contraction) and all lower extremity measurements (hip flexion, knee flexion, knee extension, and ankle dorsiflexion) will be averaged to yield upper and lower extremity megascores. Larger values indicate greater strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression</measure>
    <time_frame>16 weeks</time_frame>
    <description>Target engagement will be assessed by comparing the PBMC fold change in cytokine gene expression from baseline to week 4-16 average of ALS patients receiving drug versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cytokine Levels in the Plasma</measure>
    <time_frame>16 weeks</time_frame>
    <description>Target engagement will be assessed by mean change in plasma cytokine concentration between weeks 4 and 16 in ALS subjects receiving placebo or active drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Target engagement will be assessed by the mean change in CSF cytokine concentration between baseline and week 8 in ALS subjects receiving placebo or active drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Soluble Interleukin-6 (sIL-6) Receptor Concentrations</measure>
    <time_frame>8 weeks</time_frame>
    <description>Target engagement will be assessed by comparing the mean change in CSF sIL-6 receptor concentrations (ng/mL) between baseline and week 8 of the placebo and active drug groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measure the effects of tocilizumab on reducing glial activation measured by PBR28 PET in a subset of trial participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>ALS</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Lou Gehrig's Disease</condition>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>Active drug</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with ALS (El Escorial criteria: possible, laboratory-supported probable,
             probable or definite)

          -  Capable of providing informed consent and complying with trial procedures.

          -  High inflammatory profile of PBMC gene expression

          -  Upright SVC ≥40% of predicted value for gender, height and age at Screening and in the
             opinion of the investigator is able to comply with and complete the trial.

          -  Women must not be able to become pregnant for the duration of the study.

          -  Negative tuberculosis blood or skin test at Screening

          -  Not taking riluzole, or on a stable dosage for at least 30 days prior to Screening.

          -  Subjects medically able to undergo lumbar puncture (LP)

          -  Subjects must agree not to take live attenuated vaccines 30 days before Screening,
             throughout the duration of the trial and for 60 days following the subject's last dose
             of study drug

          -  Geographic accessibility to the study site

        Additional MRI-PET Inclusion Criteria (MGH only):

          -  High or mixed affinity to bind TSPO protein (Ala/Ala or Ala/Thr) (see section 7.1)

          -  Upper Motor Neuron Burden (UMNB) Scale Score ≥25 (out of 45) at the Screening Visit.

          -  Able to safely undergo MRI-PET scans based on the opinion of the site investigator.

        Exclusion Criteria:

          -  Prior use of Tocilizumab, cell-depleting therapies, alkylating agents, total lymphoid
             irradiation

          -  Stem cell therapies

          -  Dependence on mechanical ventilation as defined as being unable to lay supine without
             it, unable to sleep without it, or continuous daytime use

          -  Presence of tracheostomy at Screening

          -  Exposure to any anti-inflammatory agent currently under investigation for the
             treatment of patients with ALS (off label use or investigational) within 30 days prior
             to the Screening Visit (examples include NP001 and Lunasin). Medications that do not
             have an anti-inflammatory mechanism, such as mexiletine or retigabine are allowed if
             on stable dose for 30 days prior to Screening visit

          -  Treatment with a prohibited medication within 30 days of the Screening Visit

          -  Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6
             months of Screening

          -  Presence of diaphragm pacing system at Screening.

          -  Primary or secondary immunodeficiency (history of or currently active) unless related
             to primary disease under investigation

          -  History of or active diverticulitis, diverticulosis requiring antibiotic treatment,
             peptic ulcer disease, or gastrointestinal (GI) tract perforation, or chronic
             ulcerative lower GI disease such as Crohn's disease, ulcerative colitis or other
             symptomatic lower GI conditions that might predispose to perforations

          -  Known active current or history of recurrent bacterial, viral, fungal, mycobacterial
             or other opportunistic infections.

          -  History of severe allergic or anaphylactic reactions to human, humanized or murine
             monoclonal antibodies

          -  Presence of any of the following clinical conditions: bleeding diathesis, or any other
             clinical condition that would, in the opinion of the investigator, place the patient
             at increased risk during LP. Drug abuse or alcoholism within the past 12 months.
             Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active
             infectious disease, including current or prior malignancy. Rheumatic autoimmune
             disease, mixed connective tissue disease, scleroderma, polymyositis, or significant
             systemic involvement secondary to rheumatoid arthritis. Evidence of active malignant
             disease, malignancies diagnosed within the previous 5 years, or breast cancer
             diagnosed within the previous 5 years. Human immunodeficiency virus infection or other
             immunodeficient state.Uncontrolled hypertension defined as systolic blood pressure &gt;
             170 or diastolic blood pressure &gt; 110. Unstable psychiatric illness defined as
             psychosis or untreated major depression within 90 days of the Screening Visit

          -  Any major episode of infection requiring hospitalization or treatment with IV
             antibiotics within 4 weeks of screening

          -  Screening alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total
             bilirubin &gt; than 1.5 times the upper limit of normal (ULN), serum creatinine &gt; 1.6
             mg/dL in female patients and &gt; 1.9 mg/dL in male patients (patients with serum
             creatinine values exceeding limits may be eligible for the study if their estimated
             glomerular filtration rate (GFR) are &gt;30), hemoglobin &lt; 85 g/L, white blood cells &lt;
             3.0 x 109/L, absolute neutrophil count of &lt;2000/mm3, absolute lymphocyte count &lt; 0.5 x
             109/L, platelet concentration of &lt;100,000/mm3, positive Hepatitis B surface antigen
             (HBsAg)

          -  Pregnant women or women currently breastfeeding

          -  No history of chicken pox infection or no history of varicella zoster vaccination

          -  Any reason in the opinion of the investigator that the patient may not be able to
             comply with study procedures, complete the study or is unsuitable for
             immunosuppressive therapy.

        Additional MR-PET Exclusion Criteria (MGH only):

          -  Any contraindication to undergo MRI studies such as

               -  History of a cardiac pacemaker or pacemaker wires

               -  Metallic particles in the body

               -  Vascular clips in the head

               -  Prosthetic heart valves

               -  Claustrophobia

          -  Radiation exposure that exceeds the site's current guidelines

          -  Current use of tobacco products including cigarettes, e-cigarettes, cigars, snuff and
             chewing tobacco, or nicotine replacement products such as gum, or patch

          -  Taking any other anti-inflammatory or immune modulating medications except for over
             the counter NSAIDs

          -  Unwilling or unable to discontinue benzodiazepine usage (other than Lorazepam,
             Clonazepam, or Zolpidem) for one day prior to scanning
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shafeeq Ladha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Neurological Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <results_first_submitted>August 6, 2019</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barrow Neurological Institute</investigator_affiliation>
    <investigator_full_name>Shafeeq Ladha, MD</investigator_full_name>
    <investigator_title>Director, Gregory W. Fulton ALS and Neuromuscular Disease Center</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>tocilizumab</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02469896/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
        </group>
        <group group_id="P2">
          <title>Active Drug</title>
          <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
        </group>
        <group group_id="B2">
          <title>Active Drug</title>
          <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="8.6"/>
                    <measurement group_id="B2" value="61.9" spread="8.7"/>
                    <measurement group_id="B3" value="60.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Tolerant to Study Drug</title>
        <description>Tolerability will be assessed by on the proportion of participants remaining on study drug through all 3 doses and remaining on study and free from possibly drug-related and dose-limiting SAEs to the end of follow-up. Safety will be assessed by the occurrence of severe adverse events (SAEs), overall rates of adverse events (AEs), clinically significant abnormal laboratory tests, and changes in vital signs.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tolerability</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Tolerability</title>
            <description>14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Tolerant to Study Drug</title>
          <description>Tolerability will be assessed by on the proportion of participants remaining on study drug through all 3 doses and remaining on study and free from possibly drug-related and dose-limiting SAEs to the end of follow-up. Safety will be assessed by the occurrence of severe adverse events (SAEs), overall rates of adverse events (AEs), clinically significant abnormal laboratory tests, and changes in vital signs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.875</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.556</ci_lower_limit>
            <ci_upper_limit>1.377</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rates of All-cause Mortality</title>
        <description>Safety will be assessed by the occurrence of all-cause mortality.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of All-cause Mortality</title>
          <description>Safety will be assessed by the occurrence of all-cause mortality.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <other_analysis_desc>No statistical data was obtain because no patients died during the trial.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Decline in Slow Vital Capacity (SVC)</title>
        <description>Efficacy will be assessed by the change in the rate of change of SVC as measured by change in percent predicted per month. The SVC is a measure of lung capacity that is reported as the percent of the predicted value expected based on gender and height. In ALS patients, this measure declines over time as a result of progressive respiratory muscle weakness.</description>
        <time_frame>16 weeks</time_frame>
        <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline in Slow Vital Capacity (SVC)</title>
          <description>Efficacy will be assessed by the change in the rate of change of SVC as measured by change in percent predicted per month. The SVC is a measure of lung capacity that is reported as the percent of the predicted value expected based on gender and height. In ALS patients, this measure declines over time as a result of progressive respiratory muscle weakness.</description>
          <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
          <units>Percentage points change per month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.765" spread="0.829"/>
                    <measurement group_id="O2" value="-0.666" spread="0.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.922</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.902</ci_lower_limit>
            <ci_upper_limit>2.099</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Decline ALS Functional Rating Scale Revised (ALSFRS-R)</title>
        <description>Efficacy will be assessed by the mean change in ALSFRS-R total score.The ALSFRS-R scale measures the functional capabilities of an ALS patient in multiple domains such as swallowing, speech, fine motor, and breathing functions. It ranges from a maximum score of 48 for normal functioning to 0 for death or dependance on mechanical ventilation and declines by approximately 1 point per month on average for an ALS patient.</description>
        <time_frame>16 weeks</time_frame>
        <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline ALS Functional Rating Scale Revised (ALSFRS-R)</title>
          <description>Efficacy will be assessed by the mean change in ALSFRS-R total score.The ALSFRS-R scale measures the functional capabilities of an ALS patient in multiple domains such as swallowing, speech, fine motor, and breathing functions. It ranges from a maximum score of 48 for normal functioning to 0 for death or dependance on mechanical ventilation and declines by approximately 1 point per month on average for an ALS patient.</description>
          <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.583" spread="0.313"/>
                    <measurement group_id="O2" value="-0.591" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.983</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference of slopes</param_type>
            <param_value>-0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.761</ci_lower_limit>
            <ci_upper_limit>0.745</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Decline Handheld Dynamometry (HHD)</title>
        <description>Efficacy will be assessed by the change in the rate of change of HHD upper and lower extremity mega-scores. HHD utilizes an electronic pressure sensor to measure strength of individual muscles in kilograms. To calculate megascores, the mean and standard deviation of each muscle or muscle group, without regard to laterality, will be calculated from the baseline assessment of all participants. Strength estimates of each bilateral muscle or muscle group will be converted to Z scores by subtracting the relevant mean and dividing by the relevant standard deviation. Z scores for all upper extremity measurements (shoulder flexion, elbow flexion, elbow extension, wrist extension, and first dorsal interosseous contraction) and all lower extremity measurements (hip flexion, knee flexion, knee extension, and ankle dorsiflexion) will be averaged to yield upper and lower extremity megascores. Larger values indicate greater strength.</description>
        <time_frame>16 weeks</time_frame>
        <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline Handheld Dynamometry (HHD)</title>
          <description>Efficacy will be assessed by the change in the rate of change of HHD upper and lower extremity mega-scores. HHD utilizes an electronic pressure sensor to measure strength of individual muscles in kilograms. To calculate megascores, the mean and standard deviation of each muscle or muscle group, without regard to laterality, will be calculated from the baseline assessment of all participants. Strength estimates of each bilateral muscle or muscle group will be converted to Z scores by subtracting the relevant mean and dividing by the relevant standard deviation. Z scores for all upper extremity measurements (shoulder flexion, elbow flexion, elbow extension, wrist extension, and first dorsal interosseous contraction) and all lower extremity measurements (hip flexion, knee flexion, knee extension, and ankle dorsiflexion) will be averaged to yield upper and lower extremity megascores. Larger values indicate greater strength.</description>
          <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HHD Upper extremity mega-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" spread="0.035"/>
                    <measurement group_id="O2" value="-0.070" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HHD Lower extremity mega-score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.039"/>
                    <measurement group_id="O2" value="-0.032" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression</title>
        <description>Target engagement will be assessed by comparing the PBMC fold change in cytokine gene expression from baseline to week 4-16 average of ALS patients receiving drug versus placebo.</description>
        <time_frame>16 weeks</time_frame>
        <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression</title>
          <description>Target engagement will be assessed by comparing the PBMC fold change in cytokine gene expression from baseline to week 4-16 average of ALS patients receiving drug versus placebo.</description>
          <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
          <units>Fold change in gene expression</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBMC IL-6 fold-change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="0.60" upper_limit="2.54"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.52" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBMC IL-8 fold-change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="0.08" upper_limit="39.4"/>
                    <measurement group_id="O2" value="1.79" lower_limit="0.38" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PBMC Matrix Metalloproteinase 1 (MMP1)fold-change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.37" upper_limit="2.13"/>
                    <measurement group_id="O2" value="1.21" lower_limit="0.42" upper_limit="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PBMC IL-6 fold-change</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.684</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.150</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.566</ci_lower_limit>
            <ci_upper_limit>2.337</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.344</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.331</ci_lower_limit>
            <ci_upper_limit>2.080</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.198</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.691</ci_lower_limit>
            <ci_upper_limit>2.080</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cytokine Levels in the Plasma</title>
        <description>Target engagement will be assessed by mean change in plasma cytokine concentration between weeks 4 and 16 in ALS subjects receiving placebo or active drug.</description>
        <time_frame>16 weeks</time_frame>
        <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Cytokine Levels in the Plasma</title>
          <description>Target engagement will be assessed by mean change in plasma cytokine concentration between weeks 4 and 16 in ALS subjects receiving placebo or active drug.</description>
          <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
          <units>Fold change in concentration</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP (ug/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.051" lower_limit="0.279" upper_limit="3.952"/>
                    <measurement group_id="O2" value="0.049" lower_limit="0.019" upper_limit="0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta (pg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.969" lower_limit="0.608" upper_limit="1.545"/>
                    <measurement group_id="O2" value="1.266" lower_limit="0.871" upper_limit="1.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 (pg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.897" lower_limit="0.532" upper_limit="1.515"/>
                    <measurement group_id="O2" value="17.974" lower_limit="12.900" upper_limit="25.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 (pg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.241" lower_limit="0.862" upper_limit="1.787"/>
                    <measurement group_id="O2" value="1.569" lower_limit="1.169" upper_limit="2.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17 (pg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.962" lower_limit="0.470" upper_limit="1.967"/>
                    <measurement group_id="O2" value="1.342" lower_limit="0.809" upper_limit="2.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor necrosis factor (TNF)-alpha (pg/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.180" lower_limit="0.981" upper_limit="1.419"/>
                    <measurement group_id="O2" value="1.054" lower_limit="0.923" upper_limit="1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.247</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>1.306</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.828</ci_lower_limit>
            <ci_upper_limit>2.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>19.591</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.143</ci_lower_limit>
            <ci_upper_limit>34.446</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>1.264</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.892</ci_lower_limit>
            <ci_upper_limit>1.791</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.427</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>1.396</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.608</ci_lower_limit>
            <ci_upper_limit>3.206</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.285</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>0.893</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.725</ci_lower_limit>
            <ci_upper_limit>1.100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF)</title>
        <description>Target engagement will be assessed by the mean change in CSF cytokine concentration between baseline and week 8 in ALS subjects receiving placebo or active drug.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>14subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Concentration Cytokines in the Cerebrospinal Fluid (CSF)</title>
          <description>Target engagement will be assessed by the mean change in CSF cytokine concentration between baseline and week 8 in ALS subjects receiving placebo or active drug.</description>
          <units>Fold change in concentration</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP (ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.641" lower_limit="0.216" upper_limit="1.903"/>
                    <measurement group_id="O2" value="0.107" lower_limit="0.044" upper_limit="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.498" lower_limit="0.542" upper_limit="4.138"/>
                    <measurement group_id="O2" value="1.110" lower_limit="0.459" upper_limit="2.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.242" lower_limit="0.781" upper_limit="1.974"/>
                    <measurement group_id="O2" value="4.115" lower_limit="2.813" upper_limit="6.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.946" lower_limit="0.758" upper_limit="1.181"/>
                    <measurement group_id="O2" value="1.020" lower_limit="0.854" upper_limit="1.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha (pg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" lower_limit="0.727" upper_limit="1.346"/>
                    <measurement group_id="O2" value="1.066" lower_limit="0.833" upper_limit="1.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>0.167</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.643</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.604</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>0.741</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.228</ci_lower_limit>
            <ci_upper_limit>2.405</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>2.940</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.823</ci_lower_limit>
            <ci_upper_limit>4.740</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>1.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.813</ci_lower_limit>
            <ci_upper_limit>1.431</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.697</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>1.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.728</ci_lower_limit>
            <ci_upper_limit>1.595</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Soluble Interleukin-6 (sIL-6) Receptor Concentrations</title>
        <description>Target engagement will be assessed by comparing the mean change in CSF sIL-6 receptor concentrations (ng/mL) between baseline and week 8 of the placebo and active drug groups.</description>
        <time_frame>8 weeks</time_frame>
        <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Soluble Interleukin-6 (sIL-6) Receptor Concentrations</title>
          <description>Target engagement will be assessed by comparing the mean change in CSF sIL-6 receptor concentrations (ng/mL) between baseline and week 8 of the placebo and active drug groups.</description>
          <population>Discrepancies in the number of subjects analyzed are a result of subjects with missed data collection during the specific time points.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.029" lower_limit="0.886" upper_limit="1.195"/>
                    <measurement group_id="O2" value="1.836" lower_limit="1.621" upper_limit="2.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of fold change</param_type>
            <param_value>1.785</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.502</ci_lower_limit>
            <ci_upper_limit>2.121</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET)</title>
        <description>Measure the effects of tocilizumab on reducing glial activation measured by PBR28 PET in a subset of trial participants.</description>
        <time_frame>8 weeks</time_frame>
        <population>Only 2 patients met inclusion criteria for the PET portion of the study and thus, the data could not be statistically analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
          </group>
          <group group_id="O2">
            <title>Active Drug</title>
            <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Benzodiazepine Receptor 28 (PBR28) Positron Emission Tomography (PET)</title>
          <description>Measure the effects of tocilizumab on reducing glial activation measured by PBR28 PET in a subset of trial participants.</description>
          <population>Only 2 patients met inclusion criteria for the PET portion of the study and thus, the data could not be statistically analyzed.</population>
          <units>Standardized Uptake Variable Ratio(SUVR)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.225282"/>
                    <measurement group_id="O2" value="1.059685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.361542"/>
                    <measurement group_id="O2" value="1.056888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the study lasting up to 16 weeks in each subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>8 subjects will receive matching IV placebo every 4 weeks for 3 months.
Placebo: IV Infusion</description>
        </group>
        <group group_id="E2">
          <title>Active Drug</title>
          <description>16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
Tocilizumab: IV Infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Faecal Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Salivary Hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Related Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infusion Site Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Puncture Site Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gingival Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Post Lumbar Puncture Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Platelet Count Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shafeeq Ladha, MD</name_or_title>
      <organization>Barrow Neurological Institute</organization>
      <phone>602-406-8989</phone>
      <email>Shafeeq.Ladha@Barrowneuro.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

